Using antisense oligonucleotides to increase TRA2B PE splicing inclusion has been proposed as a potential therapeutic approach to reduce Tra2β protein‐coding transcripts and tumor growth [22, 51]. The gene discussed is TRA2B; the disease is neoplasm.